Authors
Jeffrey L Saver, Mayank Goyal, AAD Van der Lugt, Bijoy K Menon, Charles BLM Majoie, Diederik W Dippel, Bruce C Campbell, Raul G Nogueira, Andrew M Demchuk, Alejandro Tomasello, Pere Cardona, Thomas G Devlin, Donald F Frei, Richard Du Mesnil De Rochemont, Olvert A Berkhemer, Tudor G Jovin, Adnan H Siddiqui, Wim H Van Zwam, Stephen M Davis, Carlos Castaño, Biggya L Sapkota, Puck S Fransen, Carlos Molina, Robert J Van Oostenbrugge, Ángel Chamorro, Hester Lingsma, Frank L Silver, Geoffrey A Donnan, Ashfaq Shuaib, Scott Brown, Bruce Stouch, Peter J Mitchell, Antoni Davalos, Yvo BWEM Roos, Michael D Hill, Hermes Collaborators
Publication date
2016/9/27
Journal
Jama
Volume
316
Issue
12
Pages
1279-1289
Publisher
American Medical Association
Description
Importance
Endovascular thrombectomy with second-generation devices is beneficial for patients with ischemic stroke due to intracranial large-vessel occlusions. Delineation of the association of treatment time with outcomes would help to guide implementation.
Objective
To characterize the period in which endovascular thrombectomy is associated with benefit, and the extent to which treatment delay is related to functional outcomes, mortality, and symptomatic intracranial hemorrhage.
Design, Setting, and Patients
Demographic, clinical, and brain imaging data as well as functional and radiologic outcomes were pooled from randomized phase 3 trials involving stent retrievers or other second-generation devices in a peer-reviewed publication (by July 1, 2016). The identified 5 trials enrolled patients at 89 international sites.
Exposures
Endovascular thrombectomy plus medical therapy vs medical therapy alone; time to …
Scholar articles
JL Saver, M Goyal, AAD Van der Lugt, BK Menon… - Jama, 2016